Vincamine ameliorates hepatic fibrosis via inhibiting S100A4‐mediated farnesoid X receptor activation: based on liver microenvironment and enterohepatic circulation dependence

Vincamine significantly reverses hepatic fibrosis via inhibiting S100A4 involved in the crosstalk between macrophages and HSCs, and by activating the FXR-TGR5 pathway. Targeting the S100A4-mediated FXR dependence on modulating the liver environment may be the key target of vincamine in inhibiting hepatic fibrosis.